Evidence map›Paper›PMID 40666171›Full record

ArticleEClinicalMedicine2025

Global outbreaks of respiratory syncytial virus infections from 1960 to 2025: a systematic review and meta-analysis.

Qiuyao Duan, Jinren Pan, Lin Zheng, Zhiwen Jin, Shijian Li, Hangjie Zhang, Xiaofei Fu, Ren Chen, Zhao Yu, Shunwen Qin and 4 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Qiuyao DuanSchool of Pubic Heath, Xiamen University, Xiamen, Fujian Province, China.
Jinren PanDepartment of Infectious Diseases and Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention, China.
Lin ZhengDepartment of Infectious Diseases, Xihu District Center for Disease Control and Prevention, Hangzhou, Zhejiang Province, China.
Zhiwen JinDepartment of Infectious Diseases, Fuyang District Center for Disease Control and Prevention, Hangzhou, Zhejiang Province, China.
Shijian LiDepartment of Public Health, SUNY Old Westbury, New York, USA.
Hangjie ZhangDepartment of Infectious Diseases and Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention, China.
Xiaofei FuDepartment of Infectious Diseases, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang Province, China.
Ren ChenDepartment of Infectious Diseases, Fuyang District Center for Disease Control and Prevention, Hangzhou, Zhejiang Province, China.
Zhao YuDepartment of Infectious Diseases and Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention, China.
Shunwen QinDepartment of Infectious Diseases and Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention, China.
Xiaozhi XuJinyun County Second People's Hospital, Lishui, Zhejiang Province, China.
Yin ChenZhejiang Key Laboratory of Public Health Detection and Pathogenesis Research, Zhejiang Provincial Center for Disease Control and Prevention, China.
Jimin SunDepartment of Infectious Diseases and Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention, China.
Shelan LiuDepartment of Infectious Diseases and Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Respiratory Syncytial Virus (RSV) is a major cause of acute respiratory tract infections (ARTIs) and can trigger outbreaks in vulnerable settings such as nursing homes, pediatric wards, and neonatal intensive care units. This meta-analysis aims to investigate the prevalence, outbreak size, attack rate, and case fatality rate (CFR) of RSV outbreaks reported globally from 1960 to 2025, as well as to assess variations by geographic region, age group, season, outbreak setting, and viral genotypes. Methods: We compiled a global RSV outbreak dataset by searching publications from database inception to January 31, 2025, across MEDLINE, Embase, Global Health, CINAHL, Web of Science, LILACS, OpenGrey, CNKI, Wanfang, and ChongqingVIP. Studies were eligible if they reported data on laboratory-confirmed HRSV outbreaks in any settings (i.e., hospitals, communities, schools, kindergartens, and long-term care facilities) and among all age groups (pediatric and adult patients). There were no language restrictions (English or Chinese). Studies were excluded if they lacked a clear or inconsistent definition or based solely on serology for RSV diagnosis. We used a standardized form to extract publication characteristics, study location, and outbreak and participant information (prevalence, date and season, age, setting, attack rate, CFR, and genotypes). Two authors independently assessed eligibility, with discrepancies being resolved through discussion with a third author. Random-effects models were used to generate pooled estimates with 95% confidence intervals (CIs). The estimated annual percentage change (EAPC) was calculated to assess temporal trends in prevalence, attack rate, and CFR of RSV outbreaks. The study was registered with PROSPERO under CRD42022303015. Findings: A total of 72 articles from 25 countries were included, reporting 82 RSV outbreaks worldwide involving 2282 cases. Among these, 28 studies (reporting 30 outbreaks) provided information on RSV-related deaths, while 32 studies provided RSV genotype information. The highest outbreak rates were observed in Europe, the Americas, and Asia, especially in the winter season. The most common settings were neonatal intensive care units (30.49%), hematology wards/cancer centers (24.39%), and neonatal wards (15.85%). The median outbreak size was 13 cases (range: 3-588), and RSV-B was the most common genotype (46.88%, 15/32). RSV outbreak reporting increased from 3 in 1960-1970 to 37 in 2010-2025, while the overall CFR decreased from 12.29% (95% CI: 2.51-25.95) in the 1990s to 1.24% (95% CI: 0.01-3.73) in 2010-2025 (p < 0.05). The CFRs were the highest among the elderly (9.24%, 95% CI: 2.75-18.07), in hematology wards/cancer centers (7.56%, 95% CI: 2.56-14.15), and in RSV-A and B co-infections (6.31%, 95% CI: 0.02-18.60). The global pooled attack rate was 35.78% (95% CI: 29.16-42.67), higher in children-related outbreaks (42.29%, 95% CI: 34.53-50.23), neonatal wards (44.67%, 95% CI: 31.76-57.92), and RSV-B genotype studies (46.95%, 95% CI: 35.20-58.87). Interpretation: RSV outbreaks have contributed significantly to global morbidity since the 1960s, with increasing reports over time. While the CFRs have decreased, they remain high in certain subgroups based on age, genotype, and outbreak setting. The pooled attack rate remains substantial, particularly in healthcare settings involving RSV-B genotypes and among immunosuppressed populations. This meta-analysis underscores the importance of targeted vaccination and treatment strategies for controlling RSV outbreaks worldwide in the future. Funding: This study was supported by the Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents and Zhejiang Provincial Disease Control and Prevention Administration (2025JK008) and the Key Program of Health Commission of Zhejiang Province/Science Foundation of National Health Commission (WKJ-ZJ-2523).

Indexed as

Attack rateCase fatality rateDisease burdenOutbreak settingRespiratory syncytial virus (RSV)

Identifiers

PMID40666171
PMCPMC12257031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.